Answers are grounded in this paper and cite their sources.
Artificial intelligence (AI) is revolutionizing nanoparticle (NP)-based drug delivery by tackling design, synthesis, and optimization challenges. Traditional approaches to NP development often rely on trial-and-error methods, leading to scalability, biocompatibility, and targeted drug release inefficiencies. This review explores how AI-driven models transform the landscape of NP formulation, from enhancing drug encapsulation and optimizing release kinetics to improving targeted delivery and overcoming physiological barriers. Additionally, we examine the challenges associated with AI integration, including data limitations and model interpretability, and discuss strategies for bridging these gaps. By leveraging AI, the field of nanomedicine can accelerate the transition from laboratory research to clinical applications, ultimately improving treatment outcomes for complex diseases.
No takes yet. Share an insight, caveat, or question.
Sepinoud Azimi (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: